AU2011207061B2 - Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof - Google Patents

Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof Download PDF

Info

Publication number
AU2011207061B2
AU2011207061B2 AU2011207061A AU2011207061A AU2011207061B2 AU 2011207061 B2 AU2011207061 B2 AU 2011207061B2 AU 2011207061 A AU2011207061 A AU 2011207061A AU 2011207061 A AU2011207061 A AU 2011207061A AU 2011207061 B2 AU2011207061 B2 AU 2011207061B2
Authority
AU
Australia
Prior art keywords
naproxen
formulation
ranges
weight
nsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011207061A
Other languages
English (en)
Other versions
AU2011207061A1 (en
Inventor
Christina Armstrong
Peter Draper
Nancy Klassen
John Lopez
Sankalp Vashishtha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Ontario Ltd
Original Assignee
Catalent Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Ontario Ltd filed Critical Catalent Ontario Ltd
Publication of AU2011207061A1 publication Critical patent/AU2011207061A1/en
Application granted granted Critical
Publication of AU2011207061B2 publication Critical patent/AU2011207061B2/en
Assigned to CATALENT ONTARIO LIMITED reassignment CATALENT ONTARIO LIMITED Request to Amend Deed and Register Assignors: ACCUCAPS INDUSTRIES LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011207061A 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof Active AU2011207061B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
CA2,690,488 2010-01-19
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Publications (2)

Publication Number Publication Date
AU2011207061A1 AU2011207061A1 (en) 2012-07-26
AU2011207061B2 true AU2011207061B2 (en) 2015-05-28

Family

ID=44303618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011207061A Active AU2011207061B2 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Country Status (13)

Country Link
US (4) US9480667B2 (https=)
EP (2) EP2525789B1 (https=)
JP (2) JP5975884B2 (https=)
AU (1) AU2011207061B2 (https=)
CA (1) CA2690488C (https=)
DK (1) DK2525789T3 (https=)
ES (1) ES2880813T3 (https=)
HU (1) HUE055771T2 (https=)
MX (1) MX358636B (https=)
PL (1) PL2525789T3 (https=)
PT (1) PT2525789T (https=)
SI (1) SI2525789T1 (https=)
WO (1) WO2011088553A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
BR112021021414A2 (pt) * 2019-04-26 2022-02-15 Scherer Technologies Llc R P Composição do mini softgel de naproxeno
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600023A1 (en) * 2005-03-08 2006-09-14 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
MX9602955A (es) * 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
EP1605916A4 (en) * 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLVENT SYSTEM OF A SMOOTH MEDICAMENT WITH IMPROVED ELUTION RATE
US7582679B2 (en) * 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600023A1 (en) * 2005-03-08 2006-09-14 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents

Also Published As

Publication number Publication date
US20200046662A1 (en) 2020-02-13
MX358636B (es) 2018-08-29
JP2013517304A (ja) 2013-05-16
US20130011470A1 (en) 2013-01-10
EP2525789B1 (en) 2021-06-02
EP2525789A1 (en) 2012-11-28
US12605348B2 (en) 2026-04-21
PT2525789T (pt) 2021-07-19
MX2012008300A (es) 2012-11-23
US20170020832A1 (en) 2017-01-26
WO2011088553A1 (en) 2011-07-28
CA2690488A1 (en) 2011-07-19
ES2880813T3 (es) 2021-11-25
EP2525789A4 (en) 2014-04-30
CA2690488C (en) 2013-06-11
EP3909567B1 (en) 2026-04-29
HUE055771T2 (hu) 2021-12-28
US10463637B2 (en) 2019-11-05
PL2525789T3 (pl) 2022-01-03
SI2525789T1 (sl) 2021-12-31
US9480667B2 (en) 2016-11-01
AU2011207061A1 (en) 2012-07-26
US11896566B2 (en) 2024-02-13
DK2525789T3 (da) 2021-07-19
JP2016094462A (ja) 2016-05-26
EP3909567A1 (en) 2021-11-17
US20240139132A1 (en) 2024-05-02
JP5975884B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
US12605348B2 (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
AU701771B2 (en) Gelatin capsules containing a high concentrated acetaminophen solution
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
US6551615B1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
WO2005046727A2 (en) Ibuprofen-containing soft gelatin capsules
AU2002356421A1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
WO2003013481A1 (en) The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
JP4394447B2 (ja) アセトアミノフェン組成物
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
WO2014060855A1 (en) Pharmaceutical compositions of diclofenac or salts thereof
WO2014060856A1 (en) Pharmaceutical compositions of diclofenac or salts thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: CATALENT ONTARIO LIMITED

Free format text: FORMER NAME(S): ACCUCAPS INDUSTRIES LIMITED